PriceTargets.com logo

Veru - VERU Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $4.00
  • Forecasted Upside: 539.69%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$0.63 As of 11/20/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for VERU by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Veru Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VERU and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VERU

Analyst Price Target is $4.00
▲ +539.69% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Veru in the last 3 months. The average price target is $4.00, with a high forecast of $5.00 and a low forecast of $3.00. The average price target represents a 539.69% upside from the last price of $0.63.

This chart shows the closing price for VERU for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Veru. This rating has held steady since May 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/31/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/29/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/25/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/25/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/23/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/5/2024OppenheimerReiterated RatingOutperform ➝ Outperform$5.00 ➝ $5.00
5/14/2024B. RileyInitiated CoverageBuy$5.00
5/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$3.00
5/6/2024HC WainwrightBoost TargetBuy ➝ Buy$2.00 ➝ $3.00
4/15/2024OppenheimerReiterated RatingOutperform ➝ Outperform$7.00 ➝ $5.00
3/28/2024Raymond JamesInitiated CoverageOutperform$3.00
2/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$2.00
9/27/2023HC WainwrightReiterated RatingBuy ➝ Buy$2.00
6/7/2023Jefferies Financial GroupUpgradeUnderperform ➝ Hold
5/15/2023HC WainwrightLower Target$6.00 ➝ $2.00
4/12/2023HC WainwrightReiterated RatingBuy$6.00
4/6/2023HC WainwrightLower TargetBuy$14.00 ➝ $6.00
3/15/2023OppenheimerLower TargetOutperform$14.00 ➝ $9.00
2/14/2023OppenheimerLower TargetOutperform$20.00 ➝ $14.00
2/10/2023HC WainwrightLower TargetBuy$18.00 ➝ $14.00
12/7/2022HC WainwrightLower TargetBuy$21.00 ➝ $18.00
11/10/2022HC WainwrightLower TargetBuy$24.00 ➝ $21.00
8/11/2022Cantor FitzgeraldBoost Target$24.00 ➝ $30.00
5/18/2022Brookline Capital AcquisitionBoost TargetBuy ➝ Buy$29.00 ➝ $31.00
5/18/2022Brookline Capital ManagementBoost TargetBuy ➝ Buy$29.00 ➝ $31.00
5/13/2022Cantor FitzgeraldReiterated RatingOverweight
5/13/2022Jefferies Financial GroupBoost Target$33.00 ➝ $55.00
4/12/2022OppenheimerBoost TargetOutperform$25.00 ➝ $36.00
4/12/2022HC WainwrightBoost TargetBuy$21.00 ➝ $24.00
1/11/2022HC WainwrightReiterated RatingBuy$21.00
12/3/2021HC WainwrightReiterated RatingBuy$20.00
10/14/2021HC WainwrightReiterated RatingBuy$21.00
9/21/2021HC WainwrightReiterated RatingBuy$21.00
8/27/2021Brookline Capital ManagementReiterated RatingBuy
8/27/2021OppenheimerReiterated RatingBuy$26.00
6/28/2021HC WainwrightReiterated RatingBuy$21.00
4/13/2021Jefferies Financial GroupInitiated CoverageBuy$19.00
2/25/2021HC WainwrightLower TargetBuy$22.00 ➝ $21.00
2/11/2021OppenheimerBoost Target$19.00 ➝ $24.00
2/9/2021HC WainwrightBoost TargetBuy$12.00 ➝ $17.00
12/16/2020OppenheimerBoost TargetOutperform$9.00 ➝ $19.00
12/14/2020Brookline Capital ManagementBoost Target$13.00 ➝ $17.00
12/14/2020Cantor FitzgeraldBoost TargetOverweight$6.00 ➝ $15.00
12/10/2020HC WainwrightBoost TargetBuy$6.00 ➝ $8.00
9/21/2020OppenheimerReiterated RatingBuy$9.00
8/14/2020Brookline Capital ManagementReiterated RatingBuy
8/14/2020OppenheimerReiterated RatingBuy$9.00
6/22/2020HC WainwrightReiterated RatingBuy$6.00
5/14/2020OppenheimerBoost TargetOutperform$9.00
5/6/2020HC WainwrightReiterated RatingBuy$6.00
1/21/2020HC WainwrightReiterated RatingBuy ➝ Buy$4.50 ➝ $6.00
12/13/2019HC WainwrightReiterated RatingBuy$4.50
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.30 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024
  • 7 very positive mentions
  • 21 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
7/24/2024
  • 3 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
9/22/2024
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 1 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/21/2024

Current Sentiment

  • 1 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Veru logo
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
Read More

Today's Range

Now: $0.63
Low: $0.61
High: $0.64

50 Day Range

MA: $0.79
Low: $0.58
High: $0.93

52 Week Range

Now: $0.63
Low: $0.36
High: $1.92

Volume

606,810 shs

Average Volume

1,644,323 shs

Market Capitalization

$91.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Veru?

The following Wall Street sell-side analysts have issued research reports on Veru in the last twelve months: B. Riley, HC Wainwright, Oppenheimer Holdings Inc., and Raymond James.
View the latest analyst ratings for VERU.

What is the current price target for Veru?

0 Wall Street analysts have set twelve-month price targets for Veru in the last year. Their average twelve-month price target is $4.00, suggesting a possible upside of 539.7%. Oppenheimer Holdings Inc. has the highest price target set, predicting VERU will reach $5.00 in the next twelve months. Raymond James has the lowest price target set, forecasting a price of $3.00 for Veru in the next year.
View the latest price targets for VERU.

What is the current consensus analyst rating for Veru?

Veru currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VERU will outperform the market and that investors should add to their positions of Veru.
View the latest ratings for VERU.

What other companies compete with Veru?

Other companies that are similar to Veru include Nature's Sunshine Products, Medifast, Xeris Biopharma, Estée Lauder Companies and Prestige Consumer Healthcare. Learn More about companies similar to Veru.

How do I contact Veru's investor relations team?

Veru's physical mailing address is 48 NW 25th Street Suite 102, Miami FL, 33127. The company's listed phone number is (305) 509-6897 and its investor relations email address is [email protected]. The official website for Veru is www.veruhealthcare.com. Learn More about contacing Veru investor relations.